Syremis Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $165.0Mattributed |
|---|---|
| Latest round | series-a, $165.0M, 2025-08-01attributed |
| Founded | 2024 |
| Headquarters | Boston MA |
| Industry | bio |
| Stage | series-a |
| Website | syremisrx.com |
Syremis Therapeutics is a Tel Aviv clinical-stage biotech developing oral small molecules for schizophrenia, depression, and other psychiatric disorders. Lead drug ST-905, a once-daily M1/M4 muscarinic agonist, is in Phase 1. Co-founded by the team behind Karuna's Cobenfy and launched with a $165M Series A.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-08-01 | series-a | $165.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $165.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $165.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | syremisrx.com, read 2026-05-07 |
| Description | self-reported | syremisrx.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.